Skip to main content
Erschienen in: Annals of Hematology 9/2017

16.06.2017 | Letter to the Editor

In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study

verfasst von: Martin Cremer, Mark-Alexander Schwarzbich, Tilman Schöning, Katharina Lisenko, Anthony D. Ho, Mathias Witzens-Harig

Erschienen in: Annals of Hematology | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Teras LR, DeSantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443–459. doi:10.3322/caac.21357 CrossRef Teras LR, DeSantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443–459. doi:10.​3322/​caac.​21357 CrossRef
3.
Zurück zum Zitat Rizzieri DA, Johnson JL, Byrd JC et al (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002. Br J Haematol 165:102–111. doi:10.1111/bjh.12736 CrossRefPubMedPubMedCentral Rizzieri DA, Johnson JL, Byrd JC et al (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002. Br J Haematol 165:102–111. doi:10.​1111/​bjh.​12736 CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Maramattom LV, Hari PN, Burns LJ et al (2013) Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 19:173–179. doi:10.1016/j.bbmt.2012.11.016 CrossRefPubMed Maramattom LV, Hari PN, Burns LJ et al (2013) Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 19:173–179. doi:10.​1016/​j.​bbmt.​2012.​11.​016 CrossRefPubMed
7.
Zurück zum Zitat Peniket AJ, Ruiz de Elvira MC, Taghipour G et al (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667–678. doi:10.1038/sj.bmt.1703891 CrossRefPubMed Peniket AJ, Ruiz de Elvira MC, Taghipour G et al (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667–678. doi:10.​1038/​sj.​bmt.​1703891 CrossRefPubMed
9.
Zurück zum Zitat Awasthi A, Ayello J, Van de Ven C et al (2015) Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. Br J Haematol 171:763–775. doi:10.1111/bjh.13764 CrossRefPubMed Awasthi A, Ayello J, Van de Ven C et al (2015) Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. Br J Haematol 171:763–775. doi:10.​1111/​bjh.​13764 CrossRefPubMed
Metadaten
Titel
In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study
verfasst von
Martin Cremer
Mark-Alexander Schwarzbich
Tilman Schöning
Katharina Lisenko
Anthony D. Ho
Mathias Witzens-Harig
Publikationsdatum
16.06.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 9/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3044-4

Weitere Artikel der Ausgabe 9/2017

Annals of Hematology 9/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.